In parallel with these findings, we previously reported that MS patients display elevated CD8+CCR7+CD45RA− TCM, which tends to decrease after treatment with the immunomodulatory agent IFN-β1α (14). This evidence concerns the gene CCR7 and myeloid sarcoma.